Irritable bowel syndrome (IBS) is diagnosed based on symptoms 1 and is the most commonly diagnosed bowel disorder. 2 While this symptom-based approach has the advantage of limiting unnecessary testing 3 compared with a "diagnosis of exclusion" approach, the gastrointestinal tract has a limited symptom repertoire. Consequently, this symptom-based diagnosis captures a large but heterogeneous patient population, with multiple pathophysiological mechanisms underlying symptoms. 4 Using the Rome IV criteria, IBS subgroups are based on the predominant bowel habit, that is, IBS with constipation predominance (IBS-C), with diarrhea predominance (IBS-D), a mix between constipation and diarrhea (IBS-M) and unclassified (IBS-U). This method of classification of IBS is useful for clinical management; however, these subtypes may not reflect underlying pathophysiology. 5 While preclinical models have provided important insights, the complexity of IBS is notoriously difficult to model and mechanistic studies in humans are challenging due to their potentially invasive requirements. Therefore, new approaches are needed that might enable non-invasive studies with sufficient sensitivity and specificity to advance the field. In this issue of the journal, Lee et al focused on IBS-D patients and aimed to characterize fecal metabolite profiles of patients compared with healthy controls as well as to determine if diarrhea in and of itself can impact fecal metabolite composition. 6 This review will focus on the use of metabolomics to study IBS patients highlighting key methodological issues underlying the interpretation of these studies, whether identified molecules provide novel insights into Abstract The pathophysiology of irritable bowel syndrome and the detection of biomarkers of specific mechanisms and/or predictors of therapeutic response remain elusive. This roadblock reflects, in large part, the complexity and heterogeneity of the disorder. Recently, there has been growing evidence of a dietary and/or microbiome interaction with the host that may trigger symptoms in a subset of patients. While a number of techniques are available to examine these potential interactions, "omic" approaches such as metabolomics are becoming more widely used. Metabolomics measures hundreds and potentially thousands of known and unknown small molecule chemicals (metabolites) to provide a unique look into mechanisms that underlie symptom generation and potential predictors of therapeutic response. In this issue of the journal, Lee et al use nuclear magnetic resonance (NMR) to demonstrate the value of this approach to study IBS. This review examines the use of metabolomics to better understand IBS, focusing on what has been learned to date, practical and technical considerations, its potential for future research and how the study by Lee et al have contributed to these concepts. K E Y W O R D S irritable bowel syndrome, mass spectometry, metabolites, metabolomics, microbiota, nuclear magnetic resonance